{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:46Z","timestamp":1781585686915,"version":"3.54.5"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100017596","name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017596","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The absolute number of spontaneous adverse drug reaction (ADR) reports increased in the past in several national and international ADR databases. However, in most studies drug exposure was not considered. Our study aimed to evaluate the number of ADR reports from Germany in relation to the number of patients with outpatient drug prescriptions stratified by sex, age groups, seriousness, and reporter types (physician versus consumer). Therefore, 407\u2009882 spontaneous ADR reports from Germany, after exclusion of ADR reports related to vaccines, intentional misuses and accidental exposure, submitted between 01.01.2012 and 31.12.2021 were analyzed. The annual numbers of patients with at least one outpatient drug prescription were provided by the Central Research Institute for Ambulatory Health Care in Germany. Reporting rates per year were calculated by dividing the annual number of spontaneous ADR reports by the annual number of patients with at least one outpatient drug prescription. Between 2012 and 2021 (2.4\u2010fold), and strikingly between 2017 and 2018 (2.2\u2010fold), the annual reporting rate increased. This increase appears to be primarily driven by non\u2010serious ADR reports submitted by consumers (32.5\u2010fold increase), whereas reporting rates for serious ADRs and for reports submitted by physicians remained stable. Furthermore, the rise of non\u2010serious ADR reports from consumers was particularly apparent for females aged 12\u201317 and 18\u201364\u2009years. Overall, the observed increase of non\u2010serious ADR reports is most likely related to changes in reporting obligations for pharmaceutical companies. Our study suggests that females might report ADRs more frequently.<\/jats:p>","DOI":"10.1002\/prp2.70282","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:51:50Z","timestamp":1781239910000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of Spontaneous Adverse Drug Reaction Reporting in Germany From 2012 to 2021"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-051X","authenticated-orcid":false,"given":"Diana","family":"Dubrall","sequence":"first","affiliation":[{"name":"University of Bonn, University Hospital Bonn Institute for Medical Biometry, Informatics and Epidemiology  Bonn Germany"},{"name":"Research Division Federal Institute for Drugs and Medical Devices (BfArM)  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Domg\u00f6rgen","sequence":"additional","affiliation":[{"name":"University of Bonn, University Hospital Bonn Institute for Medical Biometry, Informatics and Epidemiology  Bonn Germany"},{"name":"Research Division Federal Institute for Drugs and Medical Devices (BfArM)  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-5639","authenticated-orcid":false,"given":"Patrick","family":"Christ","sequence":"additional","affiliation":[{"name":"University of Bonn, University Hospital Bonn Institute for Medical Biometry, Informatics and Epidemiology  Bonn Germany"},{"name":"Research Division Federal Institute for Drugs and Medical Devices (BfArM)  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Below","sequence":"additional","affiliation":[{"name":"Central Research Institute for Ambulatory Health Care in Germany  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-0317","authenticated-orcid":false,"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[{"name":"University of Bonn, University Hospital Bonn Institute for Medical Biometry, Informatics and Epidemiology  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-0891","authenticated-orcid":false,"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[{"name":"Research Division Federal Institute for Drugs and Medical Devices (BfArM)  Bonn Germany"},{"name":"Department for Dermatology and Allergy University Hospital RWTH Aachen  Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"23","key":"e_1_2_14_2_1","first-page":"393","article-title":"Frequent Adverse Drug Reactions, and Medication Groups Under Suspicion","volume":"115","author":"Dubrall D.","year":"2018","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"e_1_2_14_3_1","unstructured":"European Medicines Agency \u201cGuideline on Good Pharmacovigilance Practices (GVP) Module VI \u2013 Collection Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev 2) \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010gvp\u2010module\u2010vi\u2010collection\u2010management\u2010and\u2010submission\u2010reports\u2010suspected\u2010adverse\u2010reactions\u2010medicinal\u2010products\u2010rev\u20102_en.pdf."},{"key":"e_1_2_14_4_1","unstructured":"European Medicines Agency \u201cEudraVigilance \u201dhttps:\/\/www.ema.europa.eu\/en\/human\u2010regulatory\u2010overview\/research\u2010development\/pharmacovigilance\u2010research\u2010development\/eudravigilance."},{"key":"e_1_2_14_5_1","unstructured":"European Medicines Agency \u201c2022 Annual Report on EudraVigilance for the European Parliament the Council and the Commission Reporting Period: 1 January to 31 December 2022 \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/report\/2022\u2010annual\u2010reporteudravigilance\u2010european\u2010parliament\u2010council\u2010and\u2010commission_en.pdf."},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.09.004"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00450-X"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-015-0054-1"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528080-00007"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01137-0"},{"key":"e_1_2_14_12_1","unstructured":"\u201cDIRECTIVE 2001\/83\/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use \u201dhttps:\/\/eur\u2010lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=CONSLEG:2001L0083:20121116:EN:PDF."},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2396-y"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262002"},{"key":"e_1_2_14_15_1","unstructured":"European Medicines Agency \u201cExtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Training \u201dhttps:\/\/www.ema.europa.eu\/en\/human\u2010regulatory\/post\u2010authorisation\/data\u2010medicines\u2010iso\u2010idmp\u2010standards\/extended\u2010eudravigilance\u2010medicinal\u2010product\u2010dictionary\u2010xevmpd\u2010training."},{"key":"e_1_2_14_16_1","unstructured":"\u201cMedical Dictionary for Regulatory Activities (MedDRA) \u201dhttps:\/\/www.meddra.org\/."},{"key":"e_1_2_14_17_1","unstructured":"\u201cCentral Research Institute for Ambulatory Health Care in Germany \u201dhttps:\/\/www.zi.de\/."},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15941"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01355-8"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01359-4"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.594117"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10061015"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5235"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.05417.x"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01098-4"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1867-2"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02958-1"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-018-0244-8"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01302-7"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0080-623420140000400023"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15791"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00817.x"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0494-6"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4155"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-0392-9"},{"key":"e_1_2_14_37_1","unstructured":"Robert Koch\u2010Institut \u201cPublic Dashboard \u201dhttps:\/\/public.tableau.com\/app\/profile\/robert.koch.institut\/viz\/Gesundheit_in_Deutschland_aktuell\/GEDA_20192020\u2010EHIS."},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy6020052"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071\u2010200102060\u201000001"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-021-00398-5"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316680-000000000-00000"},{"issue":"20","key":"e_1_2_14_42_1","first-page":"1","article-title":"Evaluation of Patient Reporting of Adverse Drug Reactions to the UK \u2018Yellow Card Scheme\u2019: Literature Review, Descriptive and Qualitative Analyses, and Questionnaire Surveys","volume":"15","author":"Avery A. J.","year":"2011","journal-title":"Health Technology Assessment (Winchester)"},{"key":"e_1_2_14_43_1","unstructured":"\u201cEVAS \u2013 Evaluation and Enhancement of Analyses in Spontaneous Reporting Databases \u201dhttps:\/\/www.bfarm.de\/EN\/BfArM\/Tasks\/Research\/Drug\u2010allergies\/_node.html."},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-07973-9"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.70282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:20:49Z","timestamp":1781583649000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/prp2.70282"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70282","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70282"}}